S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Poxel Stock Forecast, Price & News

0.00 (0.00%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive PXXLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poxel and its competitors with MarketBeat's FREE daily newsletter.

PXXLF Stock Forecast (MarketRank)

Overall MarketRank

1.50 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Poxel logo


Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

PXXLF Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Private households
Current Symbol
Year Founded

Company Calendar

Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$7.77 million
Book Value
$1.27 per share


Free Float
Not Optionable

Poxel Frequently Asked Questions

Should I buy or sell Poxel stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poxel in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Poxel stock.
View analyst ratings for Poxel
or view top-rated stocks.

What is Poxel's stock price forecast for 2022?

1 brokers have issued 1-year price targets for Poxel's shares. Their PXXLF stock forecasts range from $21.00 to $21.00. On average, they expect Poxel's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts' price targets for Poxel
or view top-rated stocks among Wall Street analysts.

How has Poxel's stock price performed in 2022?

Poxel's stock was trading at $5.48 at the beginning of 2022. Since then, PXXLF stock has decreased by 61.7% and is now trading at $2.10.
View the best growth stocks for 2022 here

Who are Poxel's key executives?

Poxel's management team includes the following people:
  • Mr. Thomas Kuhn M.B.A., Pharm.D., Pharm D MBA, Co-Founder, CEO & Director
  • Dr. Sébastien Bolze Ph.D., Pharm.D., Pharm D Ph.D., Co-Founder, COO & Exec. VP
  • Dr. Pascale Fouqueray-Grellier M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs
  • Dr. Sophie Hallakou-Bozec Ph.D., Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication
  • Ms. Anne Renevot, Exec. VP & CFO
  • Dr. David E. Moller M.D., Exec. VP & Chief Scientific Officer
  • Ms. Elizabeth Woo M.B.A., Sr. VP of Investor Relations, Corp. Communications & PR
  • Mr. Quentin Durand, Exec. VP, Chief Legal Officer & Head of CSR
  • Sylvie Bertrand, VP of HR
  • Mr. Noah D. Beerman MBA, Exec. VP of Bus. Devel. & Pres of US Operations (Age 60)

What is Poxel's stock symbol?

Poxel trades on the OTCMKTS under the ticker symbol "PXXLF."

How do I buy shares of Poxel?

Shares of PXXLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poxel's stock price today?

One share of PXXLF stock can currently be purchased for approximately $2.10.

How many employees does Poxel have?

Poxel employs 50 workers across the globe.

How can I contact Poxel?

Poxel's mailing address is 259-261 Avenue Jean Jaures, Lyon I0, 69007. The official website for Poxel is www.poxel.com. The company can be reached via phone at 33-4-37-37-20-10, via email at [email protected], or via fax at 043-770-8815.

This page (OTCMKTS:PXXLF) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.